Key Takeaways
- Sector: Healthcare Healthtech & Medtech.
- Geography: Denmark.
Analysis
Bavarian Nordic, the Danish vaccine maker best known for producing vaccines against mpox, smallpox, and other infectious diseases, has confirmed it is in preliminary discussions with private equity firms Nordic Capital and Permira regarding a potential takeover.
The company stated that there is no certainty that an offer will be made or what the potential terms and timing would be. Nevertheless, the news sent Bavarian Nordic's stock soaring by 24% on Thursday, bringing its market capitalization to around $3 billion.
Nordic Capital and Permira are both experienced investors in the healthcare and life sciences sectors. This potential acquisition would align with ongoing trends in European healthcare M&A, where firms are targeting specialty pharmaceutical companies with government contracts and scalable growth.
Similar recent deals include:
- CapVest Partners considering a majority stake in Stada Arzneimittel, valuing the German drugmaker at approximately €10 billion.
- Sanofi acquiring UK-based Vicebio for up to $1.6 billion to strengthen its vaccine pipeline.
- Permira completed the £703 million acquisition of Ergomed, a CRO serving the biotech sector.
Bavarian Nordic remains a vital supplier to government vaccination programs, including contracts with the U.S. Department of Health. The company has become a strategic player in pandemic preparedness and biodefense, making it an attractive asset for long-term investors in the healthcare space.
While no offer has been finalized, the involvement of two of Europe’s most active private equity firms signals continued momentum in the consolidation of the life sciences and vaccine industry.